Sohini Das

The antitrust watchdog rejected its Director General's findings, ruling there was no evidence of anti-competitive agreements involving stockist appointments or new drug launches

Fresh registrations to stop over the next 2 years under new EV policy

Digital platforms, international operations and mobility services are emerging as key growth drivers as Tata Motors Commercial Vehicles seeks to reduce cyclicality

India's southwest monsoon from June 1 to June 23 has been almost 43% below normal, among its worst performances in the last several years

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

JLR says local manufacturing plans remain unchanged as India opens its premium vehicle market to British imports while protecting lower-cost EV segments

Jaguar will go all-electric, while Range Rover and Defender retain hybrid and combustion options as JLR pivots towards North America and future growth markets

Chronic therapies and GLP-1 adoption help broaden growth drivers as the market expands over 10 per cent in April and May

India is now among Mercedes-Benz's top 15 global markets and top five for Maybach as the carmaker bets on rising wealth and luxury demand

SDV strategy to complement pipeline of new launches across ICE, CNG and EV segments

Brokerage says India should focus on specialty medicines and incremental innovation rather than copying Big Pharma's new-drug discovery model

Scooters powered highest-ever 2W volumes, shows Siam data

Novartis launches Pluvicto, a precision treatment that delivers radiation directly to cancer cells

Mercedes-Benz India said plug-in hybrids could play a bigger role in its portfolio as most luxury-car buyers continue to favour conventional powertrains despite rising electric-vehicle adoption

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of R&D

Says higher import duties, regulatory hurdles have made chemo drugs' production unviable

India's EV sales surged 45% to a record 2.72 lakh units in May, pushing overall EV penetration above 11% for the first time amid rising fuel costs

Oncology drugmaker says soaring platinum prices, higher import duties and lengthy import approvals have made production financially unviable, worsening shortages of key chemotherapy medicines